{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:37:18Z","timestamp":1777592238156,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberous Sclerosis Complex (TSC) and Neurofibromatosis type 1 (NF1) are neurocutaneous disorders commonly characterized by neuropsychiatric comorbidities. The TAND (Tuberous Sclerosis Associated Neuropsychiatric Disorders) Checklist is currently used to quickly screen for behavioural, psychiatric, intellectual, academic, neuropsychological and psychosocial manifestations in patients with TSC. We administered the authorized Italian version of the TAND Checklist to the parents of 42 TSC patients and 42 age- and sex-matched NF1 patients, for a total of 84 individuals, aged 4\u201320\u2009years.<\/jats:p>\n                    <jats:p>Aims of this study: - to test the overall usability of the TAND Checklist in NF1, \u2212to compare the results between children and adolescents with TSC and NF1, and -to examine the association between neuropsychiatric manifestations and severity of the phenotype in terms of epilepsy severity in the TSC cohort and disease severity according to the modified version of the Riccardi severity scale in the NF1 cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>TSC cohort:<\/jats:italic>\n                      35.6% had Intellectual Disability (ID), 11.9% Specific Learning Disorders (SLD), 50.0% Attention Deficit Hyperactivity Disorder (ADHD) and 16.6% anxious\/mood disorder. 33.3% had\u00a0a formal diagnosis of Autism Spectrum Disorder (ASD). Paying attention and concentrating (61.9%), impulsivity (54.8%), temper tantrums (54.8%), anxiety (45.2%), overactivity\/hyperactivity (40.5%), aggressive outburst (40.5%), absent or delayed onset of language (40.5%), repetitive behaviors (35.7%), academic difficulties (&gt;\u200940%), deficits in attention (61.9%) and executive skills (50.0%) were the most commonly reported problems.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>NF1 cohort:<\/jats:italic>\n                      9.5% had ID, 21.4% SLD, 46.6% ADHD, and 33.3% anxious\/mood disorder. No one had a diagnosis of ASD. Commonly reported issues were paying attention and concentrating (59.5%), impulsivity (52.4%), anxiety (50.0%), overactivity\/hyperactivity (38.1%), temper tantrums (38.1%), academic difficulties (&gt;\u200940%), deficits in attention (59.5%), and executive skills (38.1%).\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Neuropsychiatric features in TSC<\/jats:italic>\n                      vs\n                      <jats:italic>NF1:<\/jats:italic>\n                      Aggressive outburst and ASD features were reported significantly more frequently in TSC than in NF1.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Neuropsychiatric manifestations and phenotype severity:<\/jats:italic>\n                      Depressed mood, absent or delayed onset of language, repetitive language, difficulties in relationship with peers, repetitive behaviors, spelling, mathematics, dual-tasking, visuo-spatial tasks, executive skills, and getting disoriented were significantly different among TSC patients with different epilepsy severity. No statistically significant differences in the NF1 subgroups were noted for any of the items in the checklist.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TAND Checklist used for TSC is acceptable and feasible to complete in a clinical setting, and is able to detect the complexity of neuropsychiatric involvement in NF1 as well. NF1 is mainly characterized by an ADHD profile, anxiety problems and SLD, while ASD features are strongly associated with TSC. In conclusion, the TAND Checklist is a useful and feasible screening tool, in both TSC and NF1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01488-4","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:03:16Z","timestamp":1599732196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1"],"prefix":"10.1186","volume":"15","author":[{"given":"Francesca","family":"Cervi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Saletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-6548","authenticated-orcid":false,"given":"Angela","family":"Peron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bulgheroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"La Briola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Canevini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aglaia","family":"Vignoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"issue":"2","key":"1488_CR1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet. 2007;44(2):81\u20138.","journal-title":"J Med Genet"},{"issue":"4","key":"1488_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"1488_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1542\/pir.2015-0118","volume":"38","author":"BR Korf","year":"2017","unstructured":"Korf BR, Bebin EM. Neurocutaneous disorders in children. Pediatr Rev. 2017;38(3):119\u201328. https:\/\/doi.org\/10.1542\/pir.2015-0118.","journal-title":"Pediatr Rev"},{"issue":"11","key":"1488_CR4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/dmcn.13526","volume":"59","author":"AC Vogel","year":"2017","unstructured":"Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol. 2017;59(11):1112\u20136.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1488_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/epi4.12286","volume":"4","author":"R Nabbout","year":"2019","unstructured":"Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA study. Epilepsia Open. 2019;4(1):73\u201384.","journal-title":"Epilepsia Open"},{"key":"1488_CR6","doi-asserted-by":"publisher","unstructured":"Canevini MP, Kotulska-Jozwiak K, Curatolo P, La Briola F, Peron A, S\u0142owi\u0144ska M, et al. Current concepts on epilepsy management in tuberous sclerosis complex. Am J Med Genet Part C Semin Med Genet. 2018;(August):1\u201310. https:\/\/doi.org\/10.1002\/ajmg.c.31652.","DOI":"10.1002\/ajmg.c.31652"},{"issue":"1","key":"1488_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, D\u2019Aug\u00e8res GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):1\u201313. https:\/\/doi.org\/10.1186\/s13023-016-0553-5.","journal-title":"Orphanet J Rare Dis"},{"key":"1488_CR8","doi-asserted-by":"publisher","unstructured":"de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA, Curatolo P. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). Am J Med Genet Part C Semin Med Genet. 2018;(May):1\u201312. https:\/\/doi.org\/10.1002\/ajmg.c.31637.","DOI":"10.1002\/ajmg.c.31637"},{"issue":"7","key":"1488_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(15)00069-1.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1488_CR10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2788.2007.01030.x","volume":"52","author":"PJ De Vries","year":"2008","unstructured":"De Vries PJ, Watson P. Attention deficits in tuberous sclerosis complex (TSC): rethinking the pathways to the endstate. J Intellect Disabil Res. 2008;52(4):348\u201357.","journal-title":"J Intellect Disabil Res"},{"issue":"7","key":"1488_CR11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/dmcn.12734","volume":"57","author":"A Lehtonen","year":"2015","unstructured":"Lehtonen A, Garg S, Roberts SA, Trump D, Evans DG, Green J, et al. Cognition in children with neurofibromatosis type 1: data from a population-based study. Dev Med Child Neurol. 2015;57(7):645\u201351.","journal-title":"Dev Med Child Neurol"},{"key":"1488_CR12","doi-asserted-by":"publisher","unstructured":"Torres Nupan MM, Velez Van Meerbeke A, L\u00f3pez Cabra CA, Herrera Gomez PM. Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Front Pediatr. 2017;5(October). https:\/\/doi.org\/10.3389\/fped.2017.00227\/full.","DOI":"10.3389\/fped.2017.00227\/full"},{"issue":"2","key":"1488_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1469-8749.2012.04399.x","volume":"55","author":"A Lehtonen","year":"2013","unstructured":"Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2013;55(2):111\u201325.","journal-title":"Dev Med Child Neurol"},{"key":"1488_CR14","doi-asserted-by":"crossref","first-page":"7146168","DOI":"10.1155\/2019\/7146168","volume":"2019","author":"S Bulgheroni","year":"2019","unstructured":"Bulgheroni S, Taddei M, Saletti V, Esposito S, Micheli R, Riva D. Visuoperceptual impairment in children with NF1: from early visual processing to procedural strategies. Behav Neurol. 2019;2019:7146168.","journal-title":"Behav Neurol"},{"issue":"12","key":"1488_CR15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1017\/S0012162206002131","volume":"48","author":"SL Hyman","year":"2006","unstructured":"Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006;48(12):973\u20137.","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"1488_CR16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/87565641.2012.695831","volume":"37","author":"NA Pride","year":"2012","unstructured":"Pride NA, Payne JM, North KN. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol. 2012;37(7):590\u2013600.","journal-title":"Dev Neuropsychol"},{"issue":"2","key":"1488_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1098-2779(2000)6:2<117::AID-MRDD5>3.0.CO;2-X","volume":"6","author":"AE Kayl","year":"2000","unstructured":"Kayl AE, Moore BD. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev. 2000;6(2):117\u201324.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"1","key":"1488_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.spen.2006.01.006","volume":"13","author":"TM Levine","year":"2006","unstructured":"Levine TM, Materek A, Abel J, O\u2019Donnell M, Cutting LE. Cognitive Profile of Neurofibromatosis Type 1. Semin Pediatr Neurol. 2006;13(1):8\u201320 Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1071909106000106?via%3Dihub. [cited 2018 Oct 10].","journal-title":"Semin Pediatr Neurol"},{"issue":"10","key":"1488_CR19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1469-8749.2012.04377.x","volume":"54","author":"K Lidzba","year":"2012","unstructured":"Lidzba K, Granstrom S, Lindenau J, Mautner V-F. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol. 2012;54(10):892\u20137.","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"1488_CR20","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1007\/s10803-018-3478-0","volume":"48","author":"S Eijk","year":"2018","unstructured":"Eijk S, Mous SE, Dieleman GC, Dierckx B, Rietman AB, de Nijs PFA, et al. Autism Spectrum disorder in an unselected cohort of children with Neurofibromatosis type 1 (NF1). J Autism Dev Disord. 2018;48(7):2278\u201385. https:\/\/doi.org\/10.1007\/s10803-018-3478-0.","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"1488_CR21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajmg.b.32612","volume":"177","author":"AB Rietman","year":"2018","unstructured":"Rietman AB, van der Vaart T, Plasschaert E, Nicholson BA, Oostenbrink R, Krab LC, et al. Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet. 2018;177(3):319\u201328.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"3","key":"1488_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jpeds.2006.04.025","volume":"149","author":"A Graf","year":"2006","unstructured":"Graf A, Landolt MA, Mori AC, Boltshauser E. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr. 2006;149(3):348\u201353. https:\/\/doi.org\/10.1016\/j.jpeds.2006.04.025.","journal-title":"J Pediatr"},{"issue":"4","key":"1488_CR23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"1488_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","volume":"52","author":"PJ De Vries","year":"2015","unstructured":"De Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr Neurol [Internet]. 2015;52(1):25\u201335. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.10.004.","journal-title":"Pediatr Neurol [Internet]."},{"issue":"1","key":"1488_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10897-017-0128-1","volume":"27","author":"L Wiener","year":"2018","unstructured":"Wiener L, Battles H, Bedoya SZ, Baldwin A, Widemann BC, Pao M. Identifying symptoms of distress in youth living with Neurofibromatosis type 1 (NF1). J Genet Couns. 2018;27(1):115\u201323.","journal-title":"J Genet Couns"},{"issue":"7","key":"1488_CR26","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1212\/WNL.0000000000002928","volume":"87","author":"KS Walsh","year":"2016","unstructured":"Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA, et al. Neurocognitive outcomes in neurofibromatosis clinical trials: recommendations for the domain of attention. Neurology. 2016;87(7):S21\u201330.","journal-title":"Neurology."},{"issue":"19","key":"1488_CR27","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/ajmg.a.31923","volume":"143A","author":"RB Noll","year":"2007","unstructured":"Noll RB, Reiter-Purtill J, Moore BD, Schorry EK, Lovell AM, Vannatta K, et al. Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A. 2007 Oct;143A(19):2261\u201373.","journal-title":"Am J Med Genet A"},{"key":"1488_CR28","doi-asserted-by":"crossref","unstructured":"Riccardi V, Smirniotopoulos J. Neurofibromatosis, phenotype, natural history, and pathogenesis. J Neuropathol Exp Neurol. 1992;51(6).","DOI":"10.1097\/00005072-199211000-00010"},{"issue":"4","key":"1488_CR29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1071-9091(98)80006-5","volume":"5","author":"DH Gutmann","year":"1998","unstructured":"Gutmann DH. Parallels between tuberous sclerosis complex and neurofibromatosis 1: common threads in the same tapestry. Semin Pediatr Neurol. 1998;5(4):276\u201386 Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1071909198800065.","journal-title":"Semin Pediatr Neurol"},{"issue":"6","key":"1488_CR30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320\u20138.","journal-title":"Trends Biochem Sci"},{"key":"1488_CR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev-genom-091416-035332","volume":"18","author":"SC Borrie","year":"2017","unstructured":"Borrie SC, Brems H, Legius E, Bagni C. Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. Annu Rev Genomics Hum Genet. 2017;18:115\u201342.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"1","key":"1488_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pediatrneurol.2014.10.006","volume":"52","author":"L Leclezio","year":"2015","unstructured":"Leclezio L, Jansen A, Whittemore VH, De Vries PJ. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol. 2015;52(1):16\u201324. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.10.006.","journal-title":"Pediatr Neurol"},{"key":"1488_CR33","doi-asserted-by":"crossref","unstructured":"Vries PJ De, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. TSC-associated neuropsychiatric disorders ( TAND ): findings from the TOSCA natural history study. 2018;1\u201313.","DOI":"10.1186\/s13023-018-0901-8"},{"issue":"2","key":"1488_CR34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/dmcn.12044","volume":"55","author":"AM van Eeghen","year":"2013","unstructured":"van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, et al. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013;55(2):146\u201353 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23205844%0A. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC4071146.","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"1488_CR35","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1017\/S0033291715000264","volume":"45","author":"PF Bolton","year":"2015","unstructured":"Bolton PF, Clifford M, Tye C, Maclean C, Humphrey A, le Mar\u00e9chal K, et al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. Psychol Med. 2015;45(11):2321\u201331 Available from: http:\/\/www.journals.cambridge.org\/abstract_S0033291715000264. [cited 2018 Oct 10].","journal-title":"Psychol Med"},{"key":"1488_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yebeh.2016.04.026","volume":"60","author":"R Moavero","year":"2016","unstructured":"Moavero R, Napolitano A, Cusmai R, Vigevano F, Fig\u00e0-Talamanca L, Calbi G, et al. White matter disruption is associated with persistent seizures in tuberous sclerosis complex. Epilepsy Behav. 2016;60:63\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2016.04.026.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1488_CR37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/dmcn.14055","volume":"61","author":"I Toldo","year":"2019","unstructured":"Toldo I, Brasson V, Miscioscia M, Pelizza MF, Manara R, Sartori S, et al. Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study. Dev Med Child Neurol. 2019;61(2):168\u201373.","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"1488_CR38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/dmcn.14144","volume":"61","author":"NS Eby","year":"2019","unstructured":"Eby NS, Griffith JL, Gutmann DH, Morris SM. Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. Dev Med Child Neurol. 2019;61(8):972\u20138.","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"1488_CR39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1469-8749.2012.04357.x","volume":"54","author":"JM Payne","year":"2012","unstructured":"Payne JM, Arnold SS, Pride NA, North KN. Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1? Dev Med Child Neurol. 2012;54(10):898\u2013904.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"1488_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0883073816683322","volume":"32","author":"D Riva","year":"2017","unstructured":"Riva D, Vago C, Erbetta A, Saletti V, Esposito S, Micheli R, et al. The key search subtest of the Behavioural assessment of the Dysexecutive syndrome in children (BADS-C) instrument reveals impaired planning without external constraints in children with Neurofibromatosis type 1. J Child Neurol. 2017;32(4):387\u201396.","journal-title":"J Child Neurol"},{"issue":"7","key":"1488_CR41","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajmg.b.32095","volume":"159 B","author":"A Pasini","year":"2012","unstructured":"Pasini A, Lo-Castro A, Di Carlo L, Pitzianti M, Siracusano M, Rosa C, et al. Detecting anxiety symptoms in children and youths with neurofibromatosis type I. Am J Med Genet Part B Neuropsychiatr Genet. 2012;159 B(7):869\u201373.","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet"},{"issue":"1","key":"1488_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1866-1955-6-1","volume":"6","author":"KE Eden","year":"2014","unstructured":"Eden KE, De Vries PJ, Moss J, Richards C, Oliver C. Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers. J Neurodev Disord. 2014;6(1):1\u201311.","journal-title":"J Neurodev Disord"},{"issue":"1","key":"1488_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0371-1","volume":"10","author":"A Vignoli","year":"2015","unstructured":"Vignoli A, La Briola F, Peron A, Turner K, Vannicola C, Saccani M, et al. Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers. Orphanet J Rare Dis. 2015;10(1):1\u20139. https:\/\/doi.org\/10.1186\/s13023-015-0371-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1488_CR44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/dmcn.12038","volume":"55","author":"KS Walsh","year":"2012","unstructured":"Walsh KS, V\u00e9lez JI, Kardel PG, Imas DM, Muenke M, Packer RJ, et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol. 2012;55(2):131\u20138.","journal-title":"Dev Med Child Neurol"},{"key":"1488_CR45","doi-asserted-by":"crossref","unstructured":"Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans D, et al. Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol. 2013;55(2):139\u201345.","DOI":"10.1111\/dmcn.12043"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01488-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:00:29Z","timestamp":1668693629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01488-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01488-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.20217\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.20217\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent to participate was obtained, and this study was approved by the Ethic\u2019s committee of our Institution (9570\/2013).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the Authors has competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}